KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $50,121.28 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the transaction, the chief executive officer now owns 278,855 shares in the company, valued at approximately $2,738,356.10. The trade was a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

KalVista Pharmaceuticals Stock Up 9.5 %

KALV traded up $0.93 during trading on Wednesday, reaching $10.71. The stock had a trading volume of 515,932 shares, compared to its average volume of 304,464. The stock has a 50 day moving average of $8.80 and a two-hundred day moving average of $10.43. The firm has a market capitalization of $529.29 million, a price-to-earnings ratio of -2.94 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. TD Cowen initiated coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective for the company. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $23.80.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Aquatic Capital Management LLC bought a new stake in KalVista Pharmaceuticals during the fourth quarter worth approximately $44,000. Tower Research Capital LLC TRC lifted its position in shares of KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 5,502 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares in the last quarter. Martin Worley Group bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth $86,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).